Melphalan-Based Transplant

http://www.oncologystat.com/journals/journal_scans/High-dose

can it be done after revlimid-dex-dox?

Good Morning Yanamom;

"Although the patients treated with a TTP regimen were healthier prior to transplantation than were those in the other groups, the 92-month OS is still a remarkable achievement. Patients who achieved a CR or underwent a second transplant also had more favorable results. The authors thus recommend that patients be treated according to an established protocol, and if possible, receive the TTP-3 regimen."

I reviewed the link you posted but couldn't find anything more concerning what is involved with the TTP-3 Regimen. Can you help me?

Take care;

Kevin

On 5/1/2008 K. C. wrote:

Good Morning Yanamom;

"Although the patients treated with a TTP regimen were healthier prior to transplantation than were those in the other groups, the 92-month OS is still a remarkable achievement. Patients who achieved a CR or underwent a second transplant also had more favorable results. The authors thus recommend that patients be treated according to an established protocol, and if possible, receive the TTP-3 regimen."

I reviewed the link you posted but couldn't find anything more concerning what is involved with the TTP-3 Regimen. Can you help me?

Take care;

Kevin

you got me there. have a look here: I think the key is in the investigator conclusions, though it is mostly greek to me.

http://www.meds.com/conrad/ash/powles.html

 though a bit of digging at the UAMS page revealed stage 2 trial

http://myeloma.uams.edu/about-myeloma/swog_0115.asp

Now I am extremely confused. At least this trial appears in both previously untreated and previously treated sections. But the article gives an impression of finished trials. frustrated.

http://multiplemyeloma.org/treatments/3.03.05.php

 Maybe this link would be clearer. 

On 5/1/2008 YanaMom wrote:

 

On 5/1/2008 K. C. wrote:

Good Morning Yanamom;

"Although the patients treated with a TTP regimen were healthier prior to transplantation than were those in the other groups, the 92-month OS is still a remarkable achievement. Patients who achieved a CR or underwent a second transplant also had more favorable results. The authors thus recommend that patients be treated according to an established protocol, and if possible, receive the TTP-3 regimen."

I reviewed the link you posted but couldn't find anything more concerning what is involved with the TTP-3 Regimen. Can you help me?

Take care;

Kevin

you got me there. have a look here: I think the key is in the investigator conclusions, though it is mostly greek to me.

http://www.meds.com/conrad/ash/powles.html

 though a bit of digging at the UAMS page revealed stage 2 trial

http://myeloma.uams.edu/about-myeloma/swog_0115.asp

Now I am extremely confused. At least this trial appears in both previously untreated and previously treated sections. But the article gives an impression of finished trials. frustrated.